X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1670) 1670
index medicus (1583) 1583
vidarabine - analogs & derivatives (1367) 1367
male (1173) 1173
female (1088) 1088
middle aged (1040) 1040
adult (857) 857
hematology (856) 856
vidarabine - administration & dosage (776) 776
aged (771) 771
vidarabine - adverse effects (702) 702
oncology (640) 640
vidarabine - therapeutic use (632) 632
fludarabine (563) 563
antineoplastic combined chemotherapy protocols - therapeutic use (480) 480
leukemia, lymphocytic, chronic, b-cell - drug therapy (455) 455
treatment outcome (445) 445
transplantation (384) 384
antineoplastic combined chemotherapy protocols - adverse effects (353) 353
transplantation conditioning - methods (319) 319
cyclophosphamide - administration & dosage (297) 297
therapy (294) 294
adolescent (290) 290
rituximab (290) 290
immunology (272) 272
antineoplastic agents - adverse effects (255) 255
transplantation, homologous (252) 252
disease-free survival (240) 240
antineoplastic agents - therapeutic use (237) 237
bone-marrow-transplantation (234) 234
cyclophosphamide (225) 225
hematopoietic stem cell transplantation - adverse effects (215) 215
abridged index medicus (213) 213
retrospective studies (206) 206
chronic lymphocytic-leukemia (204) 204
survival analysis (203) 203
leukemia (201) 201
cancer (200) 200
chemotherapy (199) 199
recurrence (191) 191
aged, 80 and over (186) 186
remission induction (185) 185
hematopoietic stem cells (176) 176
chronic lymphocytic leukemia (172) 172
stem cells (171) 171
young adult (170) 170
child (169) 169
survival rate (169) 169
hematopoietic stem cell transplantation - methods (167) 167
care and treatment (163) 163
stem-cell transplantation (161) 161
antineoplastic combined chemotherapy protocols - administration & dosage (160) 160
follow-up studies (160) 160
versus-host-disease (155) 155
graft vs host disease - prevention & control (148) 148
hematology, oncology and palliative medicine (147) 147
risk factors (145) 145
busulfan - administration & dosage (144) 144
transplantation conditioning - adverse effects (142) 142
hematopoietic stem cell transplantation (138) 138
health aspects (135) 135
antineoplastic agents (133) 133
cyclophosphamide - adverse effects (131) 131
research (128) 128
antimitotic agents (126) 126
acute myeloid-leukemia (121) 121
cytarabine - administration & dosage (121) 121
graft vs host disease - etiology (121) 121
alemtuzumab (120) 120
prognosis (118) 118
drug administration schedule (117) 117
immunosuppressive agents - therapeutic use (114) 114
antibodies, monoclonal - administration & dosage (110) 110
leukemia, lymphocytic, chronic, b-cell - mortality (109) 109
lymphoma (106) 106
survival (105) 105
antineoplastic agents - administration & dosage (103) 103
child, preschool (103) 103
combined modality therapy (102) 102
antibodies, monoclonal, murine-derived (101) 101
leukemia, myeloid, acute - drug therapy (101) 101
non-hodgkins-lymphoma (100) 100
time factors (100) 100
prospective studies (99) 99
lymphoma, non-hodgkin - drug therapy (97) 97
regimen (97) 97
transplantation conditioning (97) 97
animals (96) 96
dosage and administration (96) 96
hematologic neoplasms - therapy (94) 94
vidarabine - pharmacology (94) 94
busulfan (93) 93
leukemia, lymphocytic, chronic, b-cell - pathology (93) 93
toxicity (93) 93
medicine & public health (92) 92
acute myelogenous leukemia (91) 91
antibodies, monoclonal - therapeutic use (91) 91
vidarabine phosphate - analogs & derivatives (91) 91
cyclophosphamide - therapeutic use (90) 90
clinical trials as topic (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1640) 1640
French (22) 22
Japanese (18) 18
Chinese (14) 14
German (10) 10
Spanish (9) 9
Czech (3) 3
Hungarian (2) 2
Dutch (1) 1
Italian (1) 1
Polish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pflügers Archiv - European Journal of Physiology, ISSN 0031-6768, 6/2018, Volume 470, Issue 6, pp. 923 - 935
Sympathetic activation causes clinically important arrhythmias including atrial fibrillation (AF) and ventricular tachyarrhythmia. Although the usefulness of... 
Neurosciences | Receptors | Beta-adrenergic receptor blocker | Biomedicine | Human Physiology | Arrhythmia | Adenylyl cyclase | Molecular Medicine | Catecholamine | Drug therapy | Cell Biology | POLYMORPHIC VENTRICULAR-TACHYCARDIA | OXIDATIVE STRESS | PHYSIOLOGY | PRACTICE GUIDELINES | AMERICAN-COLLEGE | FAILURE | ATRIAL-FIBRILLATION | DISRUPTION | ADENYLYL-CYCLASE | SUDDEN CARDIAC DEATH | ASSOCIATION TASK-FORCE | Antiviral Agents - pharmacology | Herpesviridae - drug effects | Adenylyl Cyclase Inhibitors - pharmacology | Antiviral Agents - therapeutic use | Anti-Arrhythmia Agents - pharmacology | Mice, Inbred C57BL | Vidarabine - adverse effects | Arrhythmias, Cardiac - etiology | Catecholamines - toxicity | Anti-Arrhythmia Agents - therapeutic use | Vidarabine - therapeutic use | Adenylyl Cyclase Inhibitors - therapeutic use | Vidarabine - pharmacology | Arrhythmias, Cardiac - drug therapy | Animals | Myocytes, Cardiac - drug effects | Anti-Arrhythmia Agents - adverse effects | Antiviral Agents - adverse effects | Heart - drug effects | Myocytes, Cardiac - metabolism | Mice | Adenylyl Cyclase Inhibitors - adverse effects | Calcium Signaling | Prevention | Heart | Vidarabine | Complications and side effects | Medical colleges | Tachycardia | Heart beat | Atrial fibrillation | Anti-arrhythmia drugs | Physiological aspects | Cardiac arrhythmia | Phosphorylation | Reactive oxygen species | Cardiac muscle | Tachyarrhythmia | Ryanodine receptors | Cardiomyocytes | Myocytes | Heart rate | Adenylate cyclase | Fibrillation | Sarcoplasmic reticulum | Adrenergic receptors | Ventricle | Heart diseases | Calcium (reticular)
Journal Article
Blood, ISSN 0006-4971, 01/2016, Volume 127, Issue 2, pp. 208 - 215
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 01/2011, Volume 46, Issue 1, pp. 98 - 104
Dyskeratosis congenita (DC) is characterized by reticular skin pigmentation, oral leukoplakia and abnormal nails. Patients with DC have very short telomeres... 
hematopoietic cell transplantation | dyskeratosis congenita | reduced-intensity conditioning regimen | ALEMTUZUMAB | HOYERAAL-HREIDARSSON-SYNDROME | BONE-MARROW-TRANSPLANTATION | ANTITHYMOCYTE GLOBULIN | IMMUNOLOGY | FANCONI-ANEMIA | FLUDARABINE | FAILURE | TRANSPLANTATION | CORD BLOOD TRANSPLANTATION | ONCOLOGY | HEMATOLOGY | APLASTIC-ANEMIA | MELPHALAN | Antibodies, Neoplasm - therapeutic use | Cyclophosphamide - administration & dosage | Peripheral Blood Stem Cell Transplantation - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Whole-Body Irradiation - adverse effects | Young Adult | Antibodies, Monoclonal, Humanized | Cord Blood Stem Cell Transplantation - adverse effects | Antineoplastic Agents - adverse effects | Dyskeratosis Congenita - therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Pulmonary Fibrosis - etiology | Vidarabine - adverse effects | Vidarabine - analogs & derivatives | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Vidarabine - therapeutic use | Combined Modality Therapy - adverse effects | Dyskeratosis Congenita - physiopathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Pulmonary Fibrosis - prevention & control | Bone Marrow Transplantation - adverse effects | Vidarabine - administration & dosage | Antibodies, Neoplasm - adverse effects | Epithelial cells | Patient outcomes | Abnormalities | Physiological aspects | Development and progression | Transplantation | Hematopoietic stem cells | Risk factors | Index Medicus
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 1, pp. 117 - 122
Abstract Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by... 
Hematology, Oncology and Palliative Medicine | Haploidentical transplantations | Acute leukemia | HLA | Posttransplantation cyclophosphamide | Allogeneic stem cell transplant | MORTALITY | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | TRANSPLANTATION | REDUCED-INTENSITY | ACUTE-LEUKEMIA | HIGH-RISK | HAPLOTYPE | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | BLOOD | Hematologic Neoplasms - therapy | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Follow-Up Studies | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Transplantation, Homologous | Graft vs Host Disease - mortality | Antineoplastic Agents - adverse effects | Bone Marrow Transplantation | Adult | Female | Retrospective Studies | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Acute Disease | Busulfan - adverse effects | Vidarabine - adverse effects | Survival Rate | Vidarabine - analogs & derivatives | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | Aged | Vidarabine - administration & dosage | Transplantation Conditioning | Chronic Disease | Thiotepa - adverse effects | Antimitotic agents | Pneumonia | Cyclophosphamide | Bacterial pneumonia | Mortality | Bone marrow | Transplantation | Antineoplastic agents | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | CHRONIC LYMPHOCYTIC-LEUKEMIA | COMBINATION | FLUDARABINE | STUDY-GROUP GLSG | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2016, Volume 127, Issue 11, pp. 1502 - 1508
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 26, pp. 3559 - 3566
Journal Article
Medicine, ISSN 0025-7974, 09/2018, Volume 97, Issue 39, pp. e12102 - e12102
To assess treatment response and overall survival (OS) in refractory or relapsed acute myeloid leukemia (R/R AML) patients treated by different common salvage... 
CLOFARABINE | PLUS CYTARABINE | NUCLEOSIDE ANALOGS | K562 CELLS | HOMOHARRINGTONINE | INDUCTION | chemotherapy regimen | FLUDARABINE | CLADRIBINE | TRANSPLANTATION | CLAG | ACLARUBICIN | MEDICINE, GENERAL & INTERNAL | treatment response | overall survival | refractory or relapsed acute myeloid leukemia (R/R AML) | Salvage Therapy - adverse effects | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Harringtonines - adverse effects | Male | Cytarabine - adverse effects | Harringtonines - therapeutic use | Young Adult | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Retrospective Studies | Aclarubicin - therapeutic use | Mitoxantrone - adverse effects | Mitoxantrone - therapeutic use | Aclarubicin - adverse effects | Granulocyte Colony-Stimulating Factor - adverse effects | Daunorubicin - therapeutic use | Etoposide - adverse effects | Vidarabine - adverse effects | Etoposide - therapeutic use | Survival Rate | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Granulocyte Colony-Stimulating Factor - therapeutic use | Daunorubicin - adverse effects | Leukemia, Myeloid, Acute - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cladribine - therapeutic use | Aged | Cladribine - adverse effects | Salvage Therapy - methods | Cohort Studies | Chemotherapy | Relapse | Care and treatment | Patient outcomes | Methods | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2011, Volume 154, Issue 5, pp. 644 - 653
Drug‐induced immune haemolytic anaemia is a rare but serious condition. This study investigated the possibility of drug aetiology of immune haemolytic anaemia... 
immune haemolytic anaemia | drug‐induced | Berlin case‐control surveillance study | causality assessment | case‐control study | Case-control study | Causality assessment | Berlin case-control surveillance study | Immune haemolytic anaemia | Drug-induced | AUTOANTIBODIES | CEFTRIAXONE | OXALIPLATIN | FLUDARABINE | case-control study | CHRONIC LYMPHOCYTIC-LEUKEMIA | THROMBOCYTOPENIA | drug-induced | DEPENDENT ANTIBODIES | OF-THE-LITERATURE | HEMATOLOGY | CIPROFLOXACIN | Humans | Middle Aged | Male | Case-Control Studies | Young Adult | Lorazepam - adverse effects | Antineoplastic Agents - adverse effects | Drug-Related Side Effects and Adverse Reactions | Aged, 80 and over | Adult | Female | Anti-Bacterial Agents - adverse effects | Odds Ratio | Ciprofloxacin - adverse effects | Diclofenac - adverse effects | Berlin | Vidarabine - adverse effects | Anemia, Hemolytic, Autoimmune - chemically induced | Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects | Vidarabine - analogs & derivatives | Piperacillin - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anemia, Hemolytic, Autoimmune - epidemiology | Adolescent | beta-Lactams - adverse effects | Aged | Population Surveillance | Drugs | Medical colleges | Lorazepam | Beta lactamases | Immunogenetics | Ciprofloxacin | Index Medicus | Anemia | Ceftriaxone | Immunosuppressive agents | Risk factors | Diclofenac | Antibiotics | Piperacillin | fludarabine | oxaliplatin | cotrimoxazole
Journal Article
Blood, ISSN 0006-4971, 11/2004, Volume 104, Issue 10, pp. 3064 - 3071
Journal Article
Blood, ISSN 0006-4971, 06/2008, Volume 111, Issue 12, pp. 5530 - 5536
Journal Article
Blood, ISSN 0006-4971, 10/2001, Volume 98, Issue 8, pp. 2319 - 2325
To comparatively assess first-line treatment with fludarabine and 2 anthracycline-containing regimens, namely CAP (cyclophosphamide, doxorubicin plus... 
AGENT | PHOSPHATE | TRIAL | PREDNISONE | INFECTIONS | CLL | THERAPY | TERM FOLLOW-UP | HEMATOLOGY | CHLORAMBUCIL | LYMPHOID MALIGNANCIES | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Hospitalization - statistics & numerical data | Male | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Vidarabine Phosphate - analogs & derivatives | Time Factors | Phosphoramide Mustards - administration & dosage | Phosphoramide Mustards - adverse effects | Vidarabine Phosphate - adverse effects | Vincristine - administration & dosage | Female | Vidarabine Phosphate - therapeutic use | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Proportional Hazards Models | Survival Rate | Disease Progression | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Antimetabolites, Antineoplastic - therapeutic use | Sample Size | Antimetabolites, Antineoplastic - adverse effects | Cisplatin - adverse effects | Lymphocyte Count | Vincristine - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 57 - 66
Journal Article